Levocar Retard (Carbidopa, Levodopa)

Levodopa is a precursor that the brain converts into dopamine, compensating for the loss of dopaminergic neurons in Parkinsonian disorders. Carbidopa blocks the enzyme aromatic L‑amino acid decarboxylase outside the brain, preventing premature conversion of levodopa and allowing more of the drug to reach the central nervous system.

The appropriate dose of Levocar Retard is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

Safety data for Levocar Retard in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using this medication.

To request Levocar Retard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levocar Retard combines levodopa with carbidopa, offering a higher proportion of levodopa to reach the brain compared with levodopa alone. Compared with dopamine agonists, it generally provides stronger symptomatic relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors.

Levocar Retard should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Levocar Retard is taken orally, usually with a small amount of food to reduce gastrointestinal irritation. Tablets should be swallowed whole with water and not crushed or chewed unless specifically directed by a healthcare professional.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, and rare but life‑threatening reactions such as neuroleptic malignant syndrome or severe allergic responses. Patients should seek immediate medical attention if any of these occur.

Levocar Retard is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with a history of malignant neuroleptic syndrome. Clinicians must assess each patient’s medical history before prescribing.